Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Cancer Lett. 2013 May 1;331(2):220-9. doi: 10.1016/j.canlet.2013.01.004. Epub 2013 Jan 20.

Phosphorylation of 4E-BP1 predicts sensitivity to everolimus in gastric cancer cells.

Author information

  • 1Nagoya University Graduate School of Medicine, Department of Gastroenterological Surgery (Surgery II), Nagoya 466-8550, Japan. ntetsu@med.nagoya-u.ac.jp

Abstract

We studied the effect of everolimus, an inhibitor of the mammalian target of rapamycin (mTOR) on human gastric cancer cell lines. Cell proliferation in 3 of 8 cell lines was effectively inhibited by everolimus. Basal phosphorylation level of 4E-BP1 (T37/46, T70) was significantly higher in everolimus-sensitive cells than in everolimus-resistant cells. In subcutaneous xenograft model, immunohistochemistry analysis revealed that everolimus-sensitive cells expressed high levels of phospho-4E-BP1 (T37/46). In conclusion, phosphorylation of 4E-BP1 may be a predictive biomarker of everolimus sensitivity in gastric cancer.

Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

PMID:
23340172
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk